The Enterprise Value as of June 2026 (TTM) for Rapport Therapeutics, Inc. Common Stock (RAPP) is 1.33B

According to Rapport Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current Enterprise Value is 1.33B. This represents a change of 32.05% compared to the average of 1.01B of the last 4 quarters.

Rapport Therapeutics, Inc. Common Stock (RAPP) Historical Enterprise Value (quarterly & annually)

How has RAPP Enterprise Value performed in the past?

The mean historical Enterprise Value of Rapport Therapeutics, Inc. Common Stock over the last ten years is 600.61M. The current 1.33B Enterprise Value has changed 22.11% with respect to the historical average. Over the past ten years (40 quarters), RAPP's Enterprise Value was at its highest in in the March 2026 quarter at 1.41B. The Enterprise Value was at its lowest in in the March 2023 quarter at 0.

Rapport Therapeutics, Inc. Common Stock (RAPP) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Rapport Therapeutics, Inc. Common Stock Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Rapport Therapeutics, Inc. Common Stock (RAPP) Average Enterprise Value

How has RAPP Enterprise Value performed in the past?

The current Enterprise Value of Rapport Therapeutics, Inc. Common Stock (RAPP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Rapport Therapeutics, Inc. Common Stock (RAPP) Enterprise Value vs. Peers

How is RAPP’s Enterprise Value compared to its peers?

Rapport Therapeutics, Inc. Common Stock’s Enterprise Value is less than Nurix Therapeutics, Inc. (1.46B), less than Kodiak Sciences Inc. (1.79B), greater than Phathom Pharmaceuticals, Inc. (812.47M), greater than Xencor, Inc. (1.08B), greater than BridgeBio Oncology Therapeutics Inc. (570.82M), less than AnaptysBio, Inc. (2.45B), less than Mind Medicine (MindMed) Inc. (2.44B), less than UroGen Pharma Ltd. (1.53B), greater than Oculis Holding AG (441.36M), less than Septerna, Inc. (1.57B),

Build a custom stock screener for Rapport Therapeutics, Inc. Common Stock (RAPP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rapport Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Rapport Therapeutics, Inc. Common Stock (RAPP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Rapport Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.